Biomedical Catalyst – Antibody Directed Phototherapy for Oesophageal Adenocarcinoma
Lead Research Organisation:
University College London
Department Name: UNLISTED
Abstract
Oesophageal Cancer is rapidly rising and is the 4th largest cancer killer in men. This project supports combining PhotoBiotics' proprietary OptiLink technology and its own drugs with experts from Imperial College and University College London National Medical Laser Centre to develop a novel antibody-directed phototherapy (ADP) drug to treat cancer. These drugs have few side effects and tumours cannot develop drug resistance to them. We have identified a clinically-validated target and have preliminary data to show that we can tackle this for Oesophageal Cancer. Photobiotics will oversee the manufacture and testing of the drug, Imperial College will help to generate functional data and UCL will treat tumours using their established models. If successful, thus funding will lead to major interest from the pharmaceutical industry to take this into clinical trials.
Technical Summary
Oesophageal Cancer is rapidly rising and is the 4th largest cancer killer in men. This project supports combining PhotoBiotics' proprietary OptiLink technology and its own drugs with experts from Imperial College and University College London National Medical Laser Centre to develop a novel antibody-directed phototherapy (ADP) drug to treat cancer. These drugs have few side effects and tumours cannot develop drug resistance to them. We have identified a clinically-validated target and have preliminary data to show that we can tackle this for Oesophageal Cancer. Photobiotics will oversee the manufacture and testing of the drug, Imperial College will help to generate functional data and UCL will treat tumours using their established models. If successful, thus funding will lead to major interest from the pharmaceutical industry to take this into clinical trials.
People |
ORCID iD |
| Laurence Lovat (Principal Investigator) |
Publications
Butt Mohammed A.
(2015)
Evaluating the Relationship Between Clinicopathological Variables and Mortality in Patients With Esophagogastric Adenocarcinomas
in GASTROENTEROLOGY
Dunn JM
(2013)
A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett's oesophagus.
in Lasers in medical science
Haidry RJ
(2013)
Radiofrequency ablation for early oesophageal squamous neoplasia: outcomes form United Kingdom registry.
in World journal of gastroenterology
Paterson AL
(2013)
Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis.
in The Journal of pathology
Puccio I
(2015)
PWE-183 Survivin expression increases in the progression to oesophageal adenocarcinoma
in Gut
| Description | Specialist Advisor to NICE |
| Geographic Reach | National |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Impact | Approval of minimally invasive ablative therapy for treatment of dysplasia and early cancer in Barrett's oesophagus. |
| URL | http://www.nice.org.uk/guidance/CG106 |
| Title | Oesophageal cancer rat model |
| Description | Development of a method to induce oesopahgeal adenocarcinoma in the rat oesophagus in vivo. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | We were able to create oesophageal cancer and to use this for imaging to show development and metastasis of tumour in real time. We are preparing a manuscript for publication in 2020. |
| Description | Photobiotics |
| Organisation | Photobiotics |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We have done the in vivo work for targeted photodynamic therapy studies |
| Collaborator Contribution | They have made targeted antibodies conjugated to their proprietary photosensitisers. |
| Impact | Various abstracts to scientific meetings. Papers published |
| Start Year | 2010 |
| Title | Targeted PDT agent for oesophageal adenocarcinoma |
| Description | Muc1-antibody directed photodynamic therapy agent |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | This is still under initial development but if it can be made to work, would create a whole new approach to targeted cancer therapy. |
| Description | Oral presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | We run an annual national event which drew international faculty to present our findings both to researchers but also to lay members of the general public who have an interest in this subject |
| Year(s) Of Engagement Activity | 2015,2016,2017 |